T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles

Background Ex vivo chimeric antigen receptor (CAR)-T therapies have revolutionized cancer treatment. However, treatment accessibility is hindered by high costs, long manufacturing times, and the need for specialized centers and inpatient care. Strategies to generate CAR-T cells in vivo have emerged as a promising alternative that could bypass CAR-T manufacturing bottlenecks. Most current in vivo CAR-T approaches, while demonstrating encouraging preclinical efficacy, rely on transient messenger RNA (mRNA) delivery or viral vectors which both have limitations in terms of efficiency, durability, and scalability. To address these challenges, we developed a novel DNA-based targeted lipid nanoparticle (LNP) which we…

• HE
  HORIZON EUROPE Marie Sklodowska-Curie Actions

  Award: 860303
• HE
  HORIZON EUROPE European Innovation Council

  Award: 101098944